Company enters wound protector market with new SurgiSleeve™; Expands
Versaport™ bladeless optical trocar portfolio
BALTIMORE--(BUSINESS WIRE)--Apr. 17, 2013--
(NYSE: COV), a leading global provider of healthcare products, is
launching two new surgical access devices at the annual meeting of the
Society of American Gastrointestinal and Endoscopic Surgeons (SAGES),
which starts today. At the meeting, the Company also plans to conduct a
number of hands-on labs to showcase innovative surgical solutions that
address unmet clinical needs in bariatric, colorectal, hernia,
endoluminal and other procedures.
The SurgiSleeve(TM) wound protector is easy to place, and since the material is three times stronger on average than what is used in the leading competitive product, the likelihood of tearing during a procedure is reduced. (Photo: Business Wire)
Covidien enters the fast-growing wound protector market with the global
launch of SurgiSleeve™.
Used in both open and minimally invasive surgery, the new access device
protects the wound site from contamination and also provides excellent
exposure and visualization. The SurgiSleeve wound protector is easy to
place, and since the material is three times stronger on average than
what is used in the leading competitive product1, the
likelihood of tearing during a procedure is reduced.
The introduction of the Versaport™
Bladeless Optical 12 mm Trocar is the newest addition to the wide
offering of Covidien access products. It offers surgeons visualization
during trocar placement to help clinicians minimize the risk of trocar
injuries. It shares the same proprietary cannula design as the rest of
Covidien’s optical and bladeless trocar family, offering excellent
fixation for port security and stability.
“Collaborating with the global surgical community, we continue to expand
and complement our extensive product portfolio. We are focused on
delivering high quality, high value solutions that meet both clinical
and economic needs,” said Steve Blazejewski, President, Surgical
In addition to the new SurgiSleeve and Versaport devices, Covidien is
showcasing the latest enhancements to many of its most impactful
innovations, including the Sonicision™ cordless ultrasonic device,
iDrive™ Ultra powered stapling system, Endo GIA™ Tri-Staple™ technology
platform, LigaSure™ portfolio, V-Loc™ Wound Closure reload, Barrx™
ablation system, AbsorbaTack™, Parietex™ and ProGrip™ portfolios. For
more information, please visit SAGES Booth #211.
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien manufactures,
distributes and services a diverse range of industry-leading product
lines in three segments: Medical Devices, Pharmaceuticals and Medical
Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000
employees worldwide in 70 countries, and its products are sold in over
140 countries. Please visit www.covidien.com
to learn more about our business.
1. Comparison of mean strengths between SurgiSleeve™ wound
protector and Alexis® wound protector as part of a February 9, 2012
Puncture Resistance Material Evaluation (Report # 2151-002; report on
file). Statistically significant P value is 0.004.
Alexis is a registered trademark of Applied Medical Resources Corporation
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130417005387/en/
John Jordan, 508-452-4891
Lannum, CFA, 508-452-4343
Vice President, Investor Relations
Vice President, Communications
Senior Director, Investor Relations